Eli Lilly and Company (NYSE: LLY) has announced a strategic partnership with Aktis Oncology, a US-based developer of anticancer radiopharmaceuticals, to co-develop first-in-class treatments for solid tumors and diagnostic products. Under the terms of the agreement, Aktis is set to receive an upfront payment of USD 60 million, a significant equity investment from Eli Lilly, potential milestone payments reaching up to USD 1.1 billion, and sales royalties.
This collaboration positions Eli Lilly to secure development rights to a suite of products that Aktis will discover across various novel targets specified by Lilly. The partnership aims to leverage Aktis’s expertise in radiopharmaceuticals to bolster Eli Lilly’s oncology pipeline and expand treatment options for cancer patients.- Flcube.com
